Pharsight

Soolantra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5952372 GALDERMA LABS LP Method for treating rosacea using oral or topical ivermectin
Sep, 2018

(5 years ago)

US6133310 GALDERMA LABS LP Method of treatment of rosacea
Apr, 2019

(5 years ago)

US7550440 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month ago)

US8815816 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month ago)

US8093219 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month ago)

US8080530 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month ago)

US8415311 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month ago)

US11033565 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month ago)

US8470788 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month ago)

US9089587 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US9233117 GALDERMA LABS LP Treatment of inflammatory lesions of rosacea with ivermectin
Mar, 2034

(9 years from now)

US9782425 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US10206939 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

US9233118 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(9 years from now)

Soolantra is owned by Galderma Labs Lp.

Soolantra contains Ivermectin.

Soolantra has a total of 14 drug patents out of which 9 drug patents have expired.

Expired drug patents of Soolantra are:

  • US5952372
  • US6133310
  • US7550440
  • US8815816
  • US8093219
  • US8080530
  • US8415311
  • US11033565
  • US8470788

Soolantra was authorised for market use on 19 December, 2014.

Soolantra is available in cream;topical dosage forms.

Soolantra can be used as treatment of inflammatory lesions of rosacea..

The generics of Soolantra are possible to be released after 13 March, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 19, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using IVERMECTIN ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

How can I launch a generic of SOOLANTRA before it's drug patent expiration?
More Information on Dosage

SOOLANTRA family patents

Family Patents